Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.05 HKD | +5.22% | +16.34% | 0.00% |
05-24 | Hong Kong Shares End Week in Red; Sunho Biologics Gains in Debut | MT |
05-24 | Sunho Biologics Shares Rise 7% in Hong Kong Debut | MT |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net sales 1 | 3.216 | 1.85 | 17.53 |
EBITDA 1 | -64.21 | -51.54 | -59.88 |
EBIT 1 | -66.62 | -58.14 | -66.28 |
Operating Margin | -2,071.39% | -3,142.54% | -378% |
Earnings before Tax (EBT) 1 | -70.63 | -51.99 | -132.7 |
Net income 1 | -70.63 | -51.99 | -132.7 |
Net margin | -2,196.27% | -2,810.16% | -756.82% |
EPS 2 | -0.7762 | -0.5713 | -1.429 |
Free Cash Flow | - | -14.87 | 315.7 |
FCF margin | - | -803.99% | 1,800.63% |
FCF Conversion (EBITDA) | - | - | - |
FCF Conversion (Net income) | - | - | - |
Dividend per Share | - | - | - |
Announcement Date | 09/02/24 | 09/02/24 | 16/05/24 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 |
---|---|---|---|
Net Debt 1 | 150 | - | - |
Net Cash position 1 | - | 2.41 | 201 |
Leverage (Debt/EBITDA) | -2.339 x | - | - |
Free Cash Flow | - | -14.9 | 316 |
ROE (net income / shareholders' equity) | - | 78.1% | 251% |
ROA (Net income/ Total Assets) | - | -46.6% | -22.9% |
Assets 1 | - | 111.5 | 578.7 |
Book Value Per Share 2 | -1.450 | -0.0200 | -1.110 |
Cash Flow per Share 2 | 0.1200 | 0.0200 | 1.330 |
Capex 1 | 5.52 | 1.44 | 1.03 |
Capex / Sales | 171.52% | 77.78% | 5.87% |
Announcement Date | 09/02/24 | 09/02/24 | 16/05/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 136M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- 2898 Stock
- Financials Sunho Biologics, Inc.